{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-055962","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2026-08-12T12:18:05+00:00","discovered_at":"2026-08-12T12:20:01.478698+00:00","generated_at":"2026-08-12T12:20:06.637286+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Madrigal expands board to nine, appoints J&J R&D chief John C. Reed","bullets":["Board grew from 8 to 9 members; Reed elected Class II director, term to 2027 annual meeting.","Reed is EVP Innovative Medicine R&D at Johnson & Johnson, leading oncology, immunology, neuroscience research.","Compensation: $50k cash retainer, $10k for Science & Tech Committee, $675k equity grant (50% options, 50% RSUs).","Reed joins Science and Technology Committee; no material transactions disclosed under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-055962","json":"https://secwatch.observer/filing/0001628280-26-055962.json","markdown":"https://secwatch.observer/filing/0001628280-26-055962.md","text":"https://secwatch.observer/filing/0001628280-26-055962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/0001628280-26-055962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/mdgl-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:20:06.637286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03566c80c2","claim":"John C. Reed was elected as Director at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"On August 11, 2026, the Board of Directors (the \"Board\") of Madrigal Pharmaceuticals, Inc. (the \"Company\") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/0001628280-26-055962-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}